治疗疫苗候选物对树突状细胞上HBeAg pEGFP-N1-C（472-507）-ecdCD40L

StephenW

Acta Virol. 2018;62(2):157-163. doi: 10.4149/av_2018_205.
The influence of therapeutic vaccine candidate against HBeAg pEGFP-N1-C (472-507)-ecdCD40L on dendritic cells.
Zheng J, Xue H, Zhang H, Wang L, Zheng L, Wang X, Lin X, Jin S, Wu J.
Abstract

Hepatitis B virus (HBV) infection is a major public health problem and immune tolerance is responsible for persistent HBV infection. HBV therapeutic vaccines targeting HBV e antigen (HBeAg) may have an excellent effect in overcoming HBV immune tolerance. Thus, there is urgency for designing therapeutic vaccine candidates that target HBeAg. In this research, we fused the C (472-507) gene sequence of HBV with the extracellular domain of human CD40 ligand sequence and ligated this fused sequence into the pEGFP-N1 vector to construct the recombinant plasmid pEGFP-N1-C (472-507)-ecdCD40L. Then, the dendritic cells (DCs) generated from human peripheral blood were transfected with this recombinant plasmid. After this, the phenotype and function of DCs were assessed. Compared with the three control groups of pEGFP-N1-C (472-507), pEGFP-N1 and phosphate buffered saline (PBS), we found that DCs transfected with the recombinant plasmid pEGFP-N1-C (472-507)-ecdCD40L enhanced the expression of costimulatory molecules (CD80, CD86 and HLA-DR) and secretion of cytokine IL-12p70. Furthermore, the capacity of inducing the proliferation of allogeneic lymphocytes was also improved. Our study validated that transfecting DCs with recombinant plasmid pEGFP-N1-C (472-507)-ecdCD40L could activate DCs and enhance their functions. Therefore, C (472-507)-ecdCD40L fusion sequence may be a promising vaccine candidate for chronic hepatitis B therapythat targets HBeAg.
KEYWORDS:

CD40 ligand; dendritic cells; hepatitis B virus e antigens; therapeutic vaccines.

PMID:
    29895156
DOI:
    10.4149/av_2018_205

StephenW

Acta Virol。 2018; 62（2）：157-163。 doi：10.4149 / av_2018_205。
治疗疫苗候选物对树突状细胞上HBeAg pEGFP-N1-C（472-507）-ecdCD40L的影响。
郑钧薛昊张昊王，郑璐王新林X金瑾吴J.
抽象

乙型肝炎病毒（HBV）感染是主要的公共健康问题，并且免疫耐受导致持续的HBV感染。针对HBV e抗原（HBV e抗原）的HBV治疗性疫苗可能在克服HBV免疫耐受方面具有优异的效果。因此，设计靶向HBeAg的治疗性候选疫苗具有迫切性。在本研究中，我们将HBV的C（472-507）基因序列与人CD40配体序列的胞外结构域融合，并将该融合序列连接到pEGFP-N1载体中以构建重组质粒pEGFP-N1-C（472- 507）-ecdCD40L。然后，用该重组质粒转染由人外周血产生的树突细胞（DC）。之后，评估DC的表型和功能。与pEGFP-N1-C（472-507），pEGFP-N1和磷酸盐缓冲液（PBS）三个对照组相比，转染重组质粒pEGFP-N1-C（472-507）-ecdCD40L增强共刺激分子（CD80，CD86和HLA-DR）的表达和细胞因子IL-12p70的分泌。此外，诱导异基因淋巴细胞增殖的能力也得到改善。我们的研究验证了用重组质粒pEGFP-N1-C（472-507）-ecdCD40L转染DC可激活DC并增强其功能。因此，C（472-507）-ecdCD40L融合序列可能成为靶向HBeAg的慢性乙型肝炎治疗的候选疫苗。
关键词：

CD40配体;树突状细胞;乙型肝炎病毒e抗原;治疗性疫苗。

结论：
    29895156
DOI：
    10.4149 / av_2018_205